JP7182872B2 - 過敏性腸症候群の治療のための合成組成物および方法 - Google Patents

過敏性腸症候群の治療のための合成組成物および方法 Download PDF

Info

Publication number
JP7182872B2
JP7182872B2 JP2017523330A JP2017523330A JP7182872B2 JP 7182872 B2 JP7182872 B2 JP 7182872B2 JP 2017523330 A JP2017523330 A JP 2017523330A JP 2017523330 A JP2017523330 A JP 2017523330A JP 7182872 B2 JP7182872 B2 JP 7182872B2
Authority
JP
Japan
Prior art keywords
ibs
patients
symptoms
mucosal barrier
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017523330A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533915A5 (https=
JP2017533915A (ja
Inventor
ティエリー・エネ
ブルース・マコンネル
エマ・サロモンソン
ルイーセ・クリスティーネ・ヴィクスネス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycom AS
Original Assignee
Glycom AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycom AS filed Critical Glycom AS
Publication of JP2017533915A publication Critical patent/JP2017533915A/ja
Publication of JP2017533915A5 publication Critical patent/JP2017533915A5/ja
Priority to JP2021103785A priority Critical patent/JP7301093B2/ja
Application granted granted Critical
Publication of JP7182872B2 publication Critical patent/JP7182872B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A23C9/206—Colostrum; Human milk
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017523330A 2014-10-29 2015-10-29 過敏性腸症候群の治療のための合成組成物および方法 Active JP7182872B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021103785A JP7301093B2 (ja) 2014-10-29 2021-06-23 過敏性腸症候群の治療のための合成組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201470663 2014-10-29
DKPA201470663 2014-10-29
PCT/DK2015/050332 WO2016066175A1 (en) 2014-10-29 2015-10-29 Synthetic composition and method for treating irritable bowel syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021103785A Division JP7301093B2 (ja) 2014-10-29 2021-06-23 過敏性腸症候群の治療のための合成組成物および方法

Publications (3)

Publication Number Publication Date
JP2017533915A JP2017533915A (ja) 2017-11-16
JP2017533915A5 JP2017533915A5 (https=) 2018-11-08
JP7182872B2 true JP7182872B2 (ja) 2022-12-05

Family

ID=55856643

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017523330A Active JP7182872B2 (ja) 2014-10-29 2015-10-29 過敏性腸症候群の治療のための合成組成物および方法
JP2021103785A Active JP7301093B2 (ja) 2014-10-29 2021-06-23 過敏性腸症候群の治療のための合成組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021103785A Active JP7301093B2 (ja) 2014-10-29 2021-06-23 過敏性腸症候群の治療のための合成組成物および方法

Country Status (5)

Country Link
US (3) US20160346303A1 (https=)
EP (1) EP3212197A4 (https=)
JP (2) JP7182872B2 (https=)
CN (2) CN107073021A (https=)
WO (1) WO2016066175A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3209673T5 (pl) * 2014-10-24 2023-10-23 Glycom A/S Mieszaniny hmo
US11040049B2 (en) * 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
WO2021111422A1 (en) * 2019-12-06 2021-06-10 Glycom A/S Composition comprising 2'-fl and dfl for use in a method for reducing pain
EP3212197A4 (en) 2014-10-29 2018-07-11 Glycom A/S Synthetic composition and method for treating irritable bowel syndrome
US11040050B2 (en) 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
CN107846957A (zh) * 2015-03-05 2018-03-27 雀巢产品技术援助有限公司 用于改善婴儿或幼儿粪便稠度或频率的组合物
ES2886951T3 (es) 2015-09-14 2021-12-21 Glycom As Composición para su uso en la modulación de la microbiota
US10780103B2 (en) 2015-10-28 2020-09-22 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
PL3368046T3 (pl) 2015-10-28 2022-11-28 Glycom A/S Syntetyczna kompozycja i sposób modulowania funkcji mózgu i zachowania
WO2017144062A1 (en) * 2016-02-24 2017-08-31 Glycom A/S Synthetic composition for microbiota modulation
ES2924137T3 (es) 2016-05-05 2022-10-04 Glycom As Composición que comprende HMOS para uso en el tratamiento de la hipersensibilidad y/o dolor visceral mediados por mastocitos
DK3452050T3 (da) * 2016-05-05 2023-02-20 Glycom As Composition comprising hmos for the treatment of noninfectious diarrhoea
US11224605B2 (en) 2016-05-19 2022-01-18 Glycom A/S Synthetic composition
MX2018015187A (es) * 2016-08-04 2019-04-24 Nestec Sa Composiciones nutricionales con 2fl y lnnt para su uso en la prevencion y/o tratamiento de la diarrea no causada por rotavirus mediante la accion en la disbiosis de la microbiota intestinal.
BR112019005329A2 (pt) * 2016-09-19 2019-06-18 Prolacta Bioscience, Inc. composições de oligossacarídeos de leite humano purificadas
AU2016101768B4 (en) * 2016-09-28 2017-02-02 Grech, Brian James DR Treatment for Irritable Bowel Syndrome
GB201617519D0 (en) * 2016-10-14 2016-11-30 Genetic Analysis As A companion diagnostic method for use in the treatment of irritable bowel syndrome with dietary interventions or faecal microbiota transplant
CN106668034A (zh) * 2017-01-13 2017-05-17 华中科技大学同济医学院附属协和医院 L‑岩藻糖在治疗消化道病变的药品和保健品中应用
WO2018157900A1 (en) * 2017-03-01 2018-09-07 Glycom A/S Synthetic composition for microbiota modulation
CN111526879A (zh) * 2017-11-02 2020-08-11 格礼卡姆股份公司 用于减少或预防疲劳和/或改善注意力或专注力的一种或多种hmo
EP3716984B1 (en) * 2017-11-30 2024-03-20 Glycom A/S Mixture of hmos for treating wheat sensitivity
US11602545B2 (en) * 2017-12-05 2023-03-14 Glycom A/S Human milk oligosaccharides for treating migraine
SG11202004659QA (en) * 2017-12-08 2020-06-29 Jennewein Biotechnologie Gmbh Spray-dried sialyllactose
WO2019123316A1 (en) * 2017-12-22 2019-06-27 Glycom A/S Composition comprising hmos for preventing or reducing nociception
CN118452467A (zh) * 2017-12-22 2024-08-09 雀巢产品有限公司 用途是用于减少婴儿和幼儿的伤害感觉的组合物
CN112423603A (zh) 2018-07-12 2021-02-26 N·V·努特里奇亚 用于改善肠屏障完整性的营养组合物、组合物的制备以及治疗方法
CN113194960A (zh) * 2018-12-19 2021-07-30 格礼卡姆股份公司 用于治疗使用低fodmap饮食的人的组合物和方法
EP3897663A4 (en) * 2018-12-21 2022-09-07 Glycom A/S COMPOSITION AND METHOD FOR PROMOTING HEALING OF THE INTESTINAL BARRIER
WO2020250185A1 (en) * 2019-06-12 2020-12-17 Glycom A/S Human milk oligosaccharides and compositions thereof for use in preventing, managing or treating symptoms related to migraine
ES1240969Y (es) * 2019-09-18 2020-07-30 Jennewein Biotechnologie Gmbh Composiciones de cereales que contienen oligosacaridos de la leche humana
JP2023501111A (ja) * 2019-11-14 2023-01-18 グリコム・アクティーゼルスカブ 腸管における胆汁酸プロファイルを均衡させるための合成組成物
CA3161861A1 (en) * 2019-11-27 2021-06-03 Glycom A/S Mixture of hmos
IT201900023016A1 (it) * 2019-12-04 2021-06-04 Alesco Srl Formulazioni comprendenti un minerale e un polisaccaride, loro composizioni e loro uso nella supplementazione di detto minerale
US12533368B2 (en) 2019-12-06 2026-01-27 Societe Des Produits Nestle S.A. Compositions for use in the reduction of pain and/or perception of pain in infants and young children
AU2020399200A1 (en) * 2019-12-11 2022-06-09 Société des Produits Nestlé S.A. Compositions for use in the reduction of nociception and other health benefits in infants and young children
EP4255444A4 (en) * 2020-12-04 2024-10-16 Glycom A/S Human milk oligosaccharides for use in supporting maturation or improvement of sleeping patterns
WO2022124324A1 (ja) * 2020-12-09 2022-06-16 株式会社明治 アシディプロピオニバクテリウム属菌またはその処理物を含んでなる組成物
WO2022155126A1 (en) * 2021-01-12 2022-07-21 Intrinsic Medicine, Inc. Methods and compositions for supporting human health during space travel
US11712445B2 (en) 2021-04-30 2023-08-01 Sourabh Kharait Compositions and methods for improving gastrointestinal function in subjects with renal disease
US20250213600A1 (en) * 2022-03-18 2025-07-03 Meiji Co., Ltd. Composition for controlling growth of bacteria in the intestinal tract and use thereof
CN119584872A (zh) * 2022-07-21 2025-03-07 田中惠 封入有烟酰胺单核苷酸的用于改善肠道菌群的肠溶性胶囊制剂
WO2025196272A1 (en) * 2024-03-22 2025-09-25 Dsm Ip Assets B.V. Combination of mixtures of hmos with mfgm and their use
CN120570904A (zh) * 2025-07-14 2025-09-02 苏州一兮生物技术有限公司 一种用于预防和/或治疗腹泻的组合物及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120172319A1 (en) 2010-12-31 2012-07-05 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
US20120171166A1 (en) 2010-12-31 2012-07-05 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
WO2012106665A2 (en) 2011-02-04 2012-08-09 The Regents Of The University Of California Disialyllacto-n-tetraose (dslnt) or variants, isomers, analogs and derivatives thereof to prevent or inhibit bowel disease
JP2012532195A (ja) 2009-07-06 2012-12-13 チルドレンズ ホスピタル メディカル センター 乳オリゴ糖による炎症の阻害
WO2013154725A1 (en) 2012-04-13 2013-10-17 Trustees Of Boston College Prebiotic compositions and methods of use
US20140249103A1 (en) 2010-12-31 2014-09-04 Abbott Laboratories Human milk oligosaccharides to promote growth of beneficial bacteria

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663321A (en) 1984-06-26 1987-05-05 Merck & Co., Inc. Triazolobenzodiazepines and pharmaceutical use
FR2796082B1 (fr) 1999-07-07 2003-06-27 Centre Nat Rech Scient Procede de production d'oligosaccharides
WO2004026257A2 (en) 2002-09-20 2004-04-01 The Board Of Regents Of The University Of Texas System Treatment of irritable bowel syndrome and related bowel diseases
GB0312365D0 (en) 2003-05-30 2003-07-02 Univ Aston Novel 3-substituted-1, 4-benzodiazepines
AU2005288080B2 (en) * 2004-09-28 2011-10-13 Otsuka Pharmaceutical Co., Ltd. Carbostyril compound
WO2007101862A1 (en) 2006-03-09 2007-09-13 Centre National De La Recherche Scientifique (Cnrs) Method of producing sialylated oligosaccharides
US20110104282A1 (en) 2008-04-25 2011-05-05 Karolinska Institutet Innovations Ab New Therapy of Treatment of the Irritable Bowel Syndrome
CN102459294A (zh) 2009-04-07 2012-05-16 格礼卡姆股份公司 2’-o-岩藻糖基乳糖的合成
EP3241836B1 (en) 2010-02-19 2024-10-30 Glycom A/S Polymorph of a tetrasaccharide containing nacetyl-lactosamine
WO2011100979A1 (en) 2010-02-19 2011-08-25 Glycom A/S Production of 6'-o-sialyllactose and intermediates
US9119869B2 (en) * 2010-04-29 2015-09-01 Ronald J. Shebuski Mucin derived polypeptides
US9200091B2 (en) * 2010-07-12 2015-12-01 The Regents Of The University Of California Bovine milk oligosaccharides
AU2011278236A1 (en) 2010-07-16 2013-02-07 Glycom A/S Derivatization of oligosaccharides
EP2454948A1 (en) 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
WO2012113404A1 (en) 2011-02-21 2012-08-30 Glycom A/S Novel glycosyl phosphites
CN103443113A (zh) 2011-03-18 2013-12-11 格力康公司 新型含岩藻糖的糖类衍生物的合成
CN103562214B9 (zh) 2011-05-13 2016-12-14 格力康公司 人乳寡糖(hmo)或其前体的多样化
WO2012155916A1 (en) 2011-05-13 2012-11-22 Glycom A/S Manufacture of lacto-n-tetraose
CN103562401A (zh) 2011-05-13 2014-02-05 格力康公司 产生人乳寡糖(hmo)或其前体的方法
EP2760875A4 (en) 2011-09-30 2015-08-26 Glycom As SYNTHESIS OF HMO NUCLEAR STRUCTURES
WO2013091660A1 (en) 2011-12-23 2013-06-27 Glycom A/S A method for obtaining crystalline lacto-n-tetraose and lacto-n-neotetraose precursors and mixtures thereof
WO2013139344A1 (en) 2012-03-20 2013-09-26 Glycom A/S Synthesis of the trisaccharide 3-o-fucosyllactose and intermediates thereof
MY168661A (en) * 2012-03-27 2018-11-28 Abbott Lab Methods for modulating cell-mediated immunity using human milk oligosaccharides
JPWO2013161693A1 (ja) * 2012-04-27 2015-12-24 トライエックス・バイオメディカル株式会社 腸内細菌異常増殖による過敏性腸症候群の診断剤及び診断法
WO2015077233A1 (en) 2013-11-19 2015-05-28 Abbott Laboratories Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides
HK1231398A1 (zh) * 2014-04-08 2017-12-22 Abbott Laboratories 使用人乳寡糖增强对病原体的粘膜先天免疫反应和/或检测的方法
EP3212197A4 (en) 2014-10-29 2018-07-11 Glycom A/S Synthetic composition and method for treating irritable bowel syndrome
US11040050B2 (en) 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
US11040049B2 (en) 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
ES2886951T3 (es) 2015-09-14 2021-12-21 Glycom As Composición para su uso en la modulación de la microbiota
TWI715424B (zh) * 2020-01-22 2021-01-01 長春石油化學股份有限公司 電解銅箔、電極及包含其之鋰離子電池

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012532195A (ja) 2009-07-06 2012-12-13 チルドレンズ ホスピタル メディカル センター 乳オリゴ糖による炎症の阻害
US20120172319A1 (en) 2010-12-31 2012-07-05 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
US20120171166A1 (en) 2010-12-31 2012-07-05 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
US20140249103A1 (en) 2010-12-31 2014-09-04 Abbott Laboratories Human milk oligosaccharides to promote growth of beneficial bacteria
WO2012106665A2 (en) 2011-02-04 2012-08-09 The Regents Of The University Of California Disialyllacto-n-tetraose (dslnt) or variants, isomers, analogs and derivatives thereof to prevent or inhibit bowel disease
WO2013154725A1 (en) 2012-04-13 2013-10-17 Trustees Of Boston College Prebiotic compositions and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ｇ．Ｉ．Ｒｅｓｅａｒｃｈ，２００７年，Ｖｏｌ．１５，Ｎｏ．４，ｐｐ．３１５－３１９
Ｇａｓｔｒｏｅｎｔｅｒｏｌｏｇｙ，２００５年，Ｖｏｌ．１２８，ｐｐ．５４１－５５１
診断と治療，２０１０年，Ｖｏｌ．９８，Ｎｏ．９，ｐｐ．１４４９－１９５３

Also Published As

Publication number Publication date
WO2016066175A1 (en) 2016-05-06
JP2021152062A (ja) 2021-09-30
EP3212197A1 (en) 2017-09-06
CN115364113A (zh) 2022-11-22
EP3212197A4 (en) 2018-07-11
JP7301093B2 (ja) 2023-06-30
US11833165B2 (en) 2023-12-05
CN107073021A (zh) 2017-08-18
US20160346303A1 (en) 2016-12-01
US20180169122A1 (en) 2018-06-21
JP2017533915A (ja) 2017-11-16
US20210308158A1 (en) 2021-10-07
US11026959B2 (en) 2021-06-08

Similar Documents

Publication Publication Date Title
JP7301093B2 (ja) 過敏性腸症候群の治療のための合成組成物および方法
US11529364B2 (en) Synthetic composition for treating metabolic disorders
US11684630B2 (en) Synthetic composition and method for modulating brain function and behaviour
EP3452050B1 (en) Composition comprising hmos for the treatment of non-infectious diarrhoea
US11896604B2 (en) Composition comprising HMSs/HMOs and use thereof
US11278558B2 (en) Synthetic composition for microbiota modulation
US11896605B2 (en) Composition comprising HMSs/HMOs and use thereof
US11890293B2 (en) Synthetic composition for treating metabolic disorders
US20160243139A1 (en) Composition comprising HMSs/HMOs and use thereof
US20160243138A1 (en) Composition comprising HMSs/HMOs and use thereof
US10835544B2 (en) Synthetic composition for regulating satiety
US20200138838A1 (en) Composition comprising hmss/hmos and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210623

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210623

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210702

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210706

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210806

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210817

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220906

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220920

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20221004

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20221101

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20221101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221122

R150 Certificate of patent or registration of utility model

Ref document number: 7182872

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150